Hemant Varma, M.B.,B.S., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Huntington Disease | 6 | 2010 | 1144 | 0.880 |
Why?
|
| Astrocytoma | 3 | 2023 | 775 | 0.750 |
Why?
|
| Postmortem Changes | 1 | 2021 | 119 | 0.750 |
Why?
|
| SOS1 Protein | 1 | 2020 | 40 | 0.700 |
Why?
|
| Glioma | 4 | 2023 | 3455 | 0.680 |
Why?
|
| Estrogen Receptor Modulators | 3 | 2007 | 58 | 0.680 |
Why?
|
| Spinal Canal | 1 | 2019 | 41 | 0.670 |
Why?
|
| Meningeal Neoplasms | 4 | 2023 | 1248 | 0.660 |
Why?
|
| Mumps | 1 | 2020 | 71 | 0.650 |
Why?
|
| Germinal Center | 1 | 2020 | 380 | 0.600 |
Why?
|
| Meningioma | 3 | 2023 | 1218 | 0.590 |
Why?
|
| Mitochondrial Encephalomyopathies | 1 | 2016 | 40 | 0.540 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2016 | 49 | 0.540 |
Why?
|
| Encephalitis | 1 | 2020 | 438 | 0.520 |
Why?
|
| Glioblastoma | 4 | 2023 | 3482 | 0.500 |
Why?
|
| Brain Neoplasms | 8 | 2023 | 9031 | 0.480 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 181 | 0.470 |
Why?
|
| Hemangioma | 1 | 2019 | 727 | 0.460 |
Why?
|
| Cathepsin L | 1 | 2013 | 68 | 0.430 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 1374 | 0.430 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2016 | 489 | 0.430 |
Why?
|
| Hydrocephalus | 1 | 2020 | 764 | 0.430 |
Why?
|
| Spinal Neoplasms | 1 | 2019 | 716 | 0.410 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 916 | 0.400 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 865 | 0.370 |
Why?
|
| Small Molecule Libraries | 3 | 2013 | 733 | 0.370 |
Why?
|
| Retinoblastoma Protein | 2 | 2007 | 672 | 0.370 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 1405 | 0.360 |
Why?
|
| Neurodegenerative Diseases | 2 | 2010 | 1088 | 0.350 |
Why?
|
| Nerve Tissue Proteins | 4 | 2013 | 4415 | 0.330 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2010 | 1334 | 0.320 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2020 | 473 | 0.320 |
Why?
|
| Thiophenes | 1 | 2013 | 569 | 0.310 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2013 | 1076 | 0.290 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2007 | 184 | 0.290 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 4758 | 0.290 |
Why?
|
| Nuclear Proteins | 4 | 2015 | 5799 | 0.280 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 3220 | 0.260 |
Why?
|
| Organic Chemicals | 1 | 2006 | 210 | 0.260 |
Why?
|
| Brain | 3 | 2021 | 27120 | 0.260 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2023 | 938 | 0.250 |
Why?
|
| Autophagy | 1 | 2013 | 1326 | 0.240 |
Why?
|
| Microtubules | 1 | 2010 | 1074 | 0.240 |
Why?
|
| Estradiol | 2 | 2002 | 1937 | 0.230 |
Why?
|
| Mutation | 7 | 2023 | 30054 | 0.220 |
Why?
|
| Glycolysis | 1 | 2007 | 835 | 0.220 |
Why?
|
| Cell Death | 4 | 2010 | 1679 | 0.210 |
Why?
|
| Cytogenetic Analysis | 1 | 2022 | 270 | 0.200 |
Why?
|
| Oligodendroglioma | 1 | 2023 | 279 | 0.200 |
Why?
|
| Hyperbilirubinemia | 1 | 2021 | 74 | 0.190 |
Why?
|
| Neurons | 3 | 2010 | 9463 | 0.180 |
Why?
|
| Methylene Blue | 1 | 2021 | 155 | 0.180 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 168 | 0.180 |
Why?
|
| PC12 Cells | 2 | 2013 | 317 | 0.170 |
Why?
|
| Ependyma | 1 | 2020 | 56 | 0.170 |
Why?
|
| Cerebral Aqueduct | 1 | 2020 | 40 | 0.170 |
Why?
|
| Cytogenetics | 1 | 2020 | 198 | 0.170 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2000 | 257 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 3 | 2021 | 6132 | 0.170 |
Why?
|
| Mitochondria | 2 | 2016 | 3624 | 0.170 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2021 | 368 | 0.160 |
Why?
|
| Gliosis | 1 | 2020 | 245 | 0.160 |
Why?
|
| Pons | 1 | 2020 | 240 | 0.160 |
Why?
|
| Chondroma | 1 | 2018 | 53 | 0.160 |
Why?
|
| Granular Cell Tumor | 1 | 2018 | 48 | 0.150 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2000 | 410 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2019 | 430 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2022 | 2510 | 0.150 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 654 | 0.140 |
Why?
|
| Cerebral Ventricles | 1 | 2020 | 542 | 0.140 |
Why?
|
| Muscular Dystrophy, Oculopharyngeal | 1 | 2016 | 8 | 0.140 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2010 | 615 | 0.130 |
Why?
|
| High-Throughput Screening Assays | 2 | 2013 | 934 | 0.130 |
Why?
|
| Tamoxifen | 1 | 2000 | 965 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2002 | 1520 | 0.130 |
Why?
|
| Ophthalmoplegia | 1 | 2016 | 168 | 0.120 |
Why?
|
| Fatal Outcome | 1 | 2020 | 1835 | 0.120 |
Why?
|
| Thoracic Vertebrae | 1 | 2019 | 597 | 0.120 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2002 | 1935 | 0.120 |
Why?
|
| Cell Culture Techniques | 1 | 2021 | 1667 | 0.110 |
Why?
|
| Estrogens | 1 | 2000 | 1522 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 1768 | 0.110 |
Why?
|
| Humans | 24 | 2023 | 761572 | 0.110 |
Why?
|
| Apoptosis | 4 | 2021 | 9489 | 0.110 |
Why?
|
| Cell Survival | 3 | 2023 | 5791 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2010 | 18253 | 0.100 |
Why?
|
| Breast Neoplasms | 3 | 2007 | 21017 | 0.100 |
Why?
|
| Middle Aged | 7 | 2021 | 220920 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2019 | 2665 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2010 | 23447 | 0.100 |
Why?
|
| Prognosis | 3 | 2021 | 29629 | 0.090 |
Why?
|
| Reactive Oxygen Species | 2 | 2010 | 2141 | 0.090 |
Why?
|
| Male | 9 | 2022 | 360842 | 0.090 |
Why?
|
| Adult | 6 | 2022 | 221203 | 0.090 |
Why?
|
| Parietal Lobe | 1 | 2015 | 852 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 2057 | 0.090 |
Why?
|
| Rats | 3 | 2013 | 23741 | 0.090 |
Why?
|
| Pituitary Neoplasms | 1 | 2018 | 1324 | 0.080 |
Why?
|
| Cyclin D1 | 2 | 2002 | 451 | 0.080 |
Why?
|
| Biopsy | 1 | 2021 | 6766 | 0.080 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2010 | 234 | 0.080 |
Why?
|
| Enzyme Activation | 2 | 2007 | 3597 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2021 | 641 | 0.080 |
Why?
|
| Necrosis | 1 | 2013 | 1611 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 3617 | 0.080 |
Why?
|
| Cyclin A | 1 | 2007 | 60 | 0.070 |
Why?
|
| Rotenone | 1 | 2007 | 45 | 0.070 |
Why?
|
| Plicamycin | 1 | 2007 | 12 | 0.070 |
Why?
|
| Animals | 10 | 2023 | 168467 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2016 | 2571 | 0.070 |
Why?
|
| Lithium Chloride | 1 | 2007 | 82 | 0.070 |
Why?
|
| Receptors, Estrogen | 2 | 2007 | 2208 | 0.070 |
Why?
|
| Culture Media, Serum-Free | 1 | 2006 | 148 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2023 | 3816 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2007 | 360 | 0.070 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2010 | 569 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2007 | 2456 | 0.070 |
Why?
|
| Infant | 2 | 2020 | 36192 | 0.070 |
Why?
|
| Transfection | 2 | 2006 | 5774 | 0.070 |
Why?
|
| Protein Biosynthesis | 1 | 2013 | 2112 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 36429 | 0.060 |
Why?
|
| Cell Line, Transformed | 1 | 2006 | 866 | 0.060 |
Why?
|
| Base Sequence | 1 | 2016 | 12441 | 0.060 |
Why?
|
| Cell Line | 2 | 2010 | 15601 | 0.060 |
Why?
|
| Macrophages | 1 | 2020 | 5769 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2007 | 5305 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2007 | 698 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2006 | 731 | 0.060 |
Why?
|
| Caspases | 1 | 2007 | 879 | 0.060 |
Why?
|
| Disease Progression | 1 | 2021 | 13510 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2023 | 16986 | 0.060 |
Why?
|
| Female | 7 | 2022 | 392686 | 0.060 |
Why?
|
| Aged | 3 | 2021 | 169310 | 0.060 |
Why?
|
| NAD | 1 | 2007 | 614 | 0.050 |
Why?
|
| Peptides | 2 | 2013 | 4358 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2000 | 6346 | 0.050 |
Why?
|
| Mice | 5 | 2023 | 81533 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2010 | 1974 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2006 | 1880 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2021 | 2865 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 3076 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2007 | 1989 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2007 | 1608 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2023 | 380 | 0.040 |
Why?
|
| Neuroprotective Agents | 1 | 2007 | 957 | 0.040 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2002 | 557 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2023 | 10448 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 3877 | 0.040 |
Why?
|
| G1 Phase | 1 | 2000 | 403 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2007 | 1712 | 0.040 |
Why?
|
| Caenorhabditis elegans | 1 | 2007 | 1456 | 0.040 |
Why?
|
| Morpholines | 1 | 2021 | 581 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2020 | 42230 | 0.030 |
Why?
|
| Dura Mater | 1 | 2018 | 290 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2022 | 80646 | 0.030 |
Why?
|
| Proteins | 1 | 2010 | 6032 | 0.030 |
Why?
|
| Protein Binding | 1 | 2008 | 9353 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 58986 | 0.030 |
Why?
|
| Adolescent | 2 | 2022 | 88324 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2022 | 1336 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 1626 | 0.030 |
Why?
|
| Cell Division | 1 | 2002 | 4465 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2010 | 18965 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 2020 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 1486 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2000 | 3792 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2002 | 2448 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 59255 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 3733 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2021 | 4280 | 0.020 |
Why?
|
| Child | 1 | 2020 | 80156 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2002 | 8321 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 2450 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2015 | 851 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 4513 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2023 | 4652 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2002 | 12794 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2023 | 8552 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2007 | 2048 | 0.010 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2007 | 874 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2007 | 1616 | 0.010 |
Why?
|
| Longevity | 1 | 2007 | 1065 | 0.010 |
Why?
|
| Aging | 1 | 2007 | 8711 | 0.000 |
Why?
|
| Transcription Factors | 1 | 2007 | 12129 | 0.000 |
Why?
|